EVIDENCE LIBRARY
Lafora Disease Case Replaced Broad Polypharmacy With a Regimen Including Clobazam
A Lafora disease report described improved seizure control and alertness after a stepwise medication revision. Removing medicines and adding others occurred within the same treatment course.
A Lafora disease report described improved seizure control and alertness after a stepwise medication revision. Removing medicines and adding others occurred within the same treatment course.
What changed
An eighteen-year-old patient had intractable seizures, myoclonus, and cognitive regression. The initial regimen included valproate, carbamazepine, phenytoin, and phenobarbitone, with concern about adverse interactions and worsening neurologic status.
The authors described withdrawing unsuitable agents and introducing a revised regimen including levetiracetam, clobazam, and perampanel. Seizure control and alertness improved.
Why attribution remains limited
This was one patient with progressive disease, without a controlled comparison of clobazam alone. Reduced medication burden, withdrawal of aggravating agents, and several additions could all influence the outcome.
The case supports careful reconstruction of a polypharmacy history and the timing of changes. It does not establish that clobazam reversed the underlying disease or that the same combination will have the same effect elsewhere. Improved alertness should be reported alongside seizure outcomes rather than assuming that any added sedative necessarily worsened cognition.
Source paper
Original analysis of the supplied journal article, identified as PMC13237742.